Cost cuts factor into Q1 as Pfizer posts better-than-expected results

Pfizer (NYSE: PFE) reported first-quarter 2025 earnings on Tuesday that beat Wall Street expectations, boosted by ongoing cost-cutting efforts and strong demand for its heart disease drug Vyndaqel (tafamidis).

The US drugmaker posted adjusted earnings per share of 92 cents, up 12% from a year earlier, compared with analysts’ forecasts of 66 cents. Revenue for the quarter came in at $13.7 billion, down 8% from the prior year and slightly below consensus expectations of $13.91 billion.

Key growth drivers included a 33% operational sales increase for the Vyndaqel family and a 62% operational rise in sales of COVID-19 vaccine Comirnaty (tozinameran). However, overall revenue declined, largely due to a steep 75% drop in Paxlovid (nirmatrelvir/ritonavir) sales. Other underperformers included Eliquis (apixaban), down 4%, and Xeljanz (tofacitinib), which fell 31%.